Book a Meeting

Non-Fucosylated Anti-Human Urokinase-type plasminogen activator (U33) Therapeutic Antibody (CAT#: BioBet-1504ZP) Datasheet

Target
Urokinase-type plasminogen activator
Isotype
IgG
Description
ADCC-Enhanced anti-Urokinase-type plasminogen activator (U33) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Urokinase-type plasminogen activator antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PLAU
Full Name
plasminogen activator, urokinase
Background
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimers disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2009]
Alternative Names
PLAU; plasminogen activator, urokinase; ATF; QPD; UPA; URK; u-PA; BDPLT5; urokinase-type plasminogen activator; U-plasminogen activator; plasminogen activator, urinary;
Gene ID
5328
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with PLAU include Quebec Platelet Disorder and Alzheimer Disease.
Related Pathways
Its related pathways are Transcriptional misregulation in cancer and E2F transcription factor network.
Function
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Metabolism antibody; Neuroscience antibody
Post-translational modifications
Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
U33
Host
Human
Species Reactivity
Human
Description
The antibody specifically bind to urokinase-type plasminogen activator (uPA), and use for cancer treatment.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany